cr.appliance – Successfully Focused on Counseling in Drug Development For 5 Years

posted in: news | 0

Radolfzell, Germany, December 5th 2012: Since 5 years the cr.appliance team with its current staff and portfolio counsels pharmaceutical companies in drug development, especially in the early stages (preclinical / clinical interface). Big international as well as mid-sized companies and biotec enterprises particularly benefit from cr.appliance’s specific expertise.

DDI Workshop 2012, Marbach Castle, May 16th

posted in: news | 0

The organisation team of the Third International DDI (drug-drug interactions) Workshop has expressed great satisfaction with the course of the scientific meeting. The participants of the DDI Workshop commended the very high scientific level of the presentations and valuable and inspiring discussions of the different topics. Without a doubt, the DDI Workshop at Marbach Castle is a well established platform for the annual exchange between experts, scientists, members of the industry and regulatory bodies regarding DDI affairs. This year more than 80 experts from 14 countries attended the DDI Workshop. The speakers came from 6 different countries (USA, Germany, Great Britain, Finland, Sweden, and New Zealand), thereof 5 from the US. They presented scientific news, the content of the draft guidelines and state of the art lectures. The scientific sessions covered different aspects to current regulatory issues, UGTbased DDIs, transporter-based DDIs and pharmacodynamic DDIs.

DDI Workshop 2012, Marbach Castle, March 27th

posted in: news | 0

The organisation team reports the final programme of the DDI 2012 – 3rd International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions. The topics of the 3rd Marbach Castle meeting, which will take place from May 6 th to 8 th 2012, will be covered by international scientists and distinguished experts from academia, pharmaceutical companies, contract research organizations, consultancies and regulatory bodies. The programme will provide a unique opportunity for scientific exchange and networking across company and organizational borders, and an opportunity to learn about the current state-of-the-art in the investigation of DDIs.